. 2022 Jun 8;31(11-12):322–333. doi: 10.1089/scd.2022.0004

Table 2.

Effects of IL-4, IL-13, and IL-10 on Lymphatic Endothelial Cell Marker Expression in CSF-1-Primed Cells

Target Treatment	Lyve-1	Pdpn	Stab1	Colec12	Itgα9
Percent of positive cells^a
None (Ex vivo)^b	5.45 ± 0.15	6.03 ± 0.74	3.13 ± 0.26	2.23 ± 0.09	7.15 ± 0.15
CSF-1	26.20 ± 1.50	91.20 ± 0.10	27.60 ± 0.80	41.00 ± 5.10	28.50 ± 9.00
IL-4	N/D	N/D	N/D	N/D	N/D
CSF-1 + IL-4	47.60 ± 1.10^*	64.30 ± 2.20	65.10 ± 5.80^*	54.20 ± 4.40^*	30.20 ± 1.30
IL-13	N/D	N/D	N/D	N/D	N/D
CSF-1 + IL-13	76.90 ± 0.50^*	88.60 ± 0.80	74.80 ± 2.00^*	65.90 ± 2.40^*	41.50 ± 2.60^*
IL-10	N/D	N/D	N/D	N/D	N/D
CSF-1 + IL-10	54.30 ± 7.60^*	98.90 ± 0.20^*	80.30 ± 3.30^*	62.40 ± 2.80^*	75.20 ± 5.40^*
Mean fluorescent intensity ( × 10³)^a
None (Ex Vivo)	20.75 ± 1.55	36.83 ± 1.79	22.16 ± 1.42	26.86 ± 6.19	56.09 ± 1.54
CSF-1	57.60 ± 0.00	149.90 ± 38.40	94.70 ± 1.10	133.20 ± 4.20	216.20 ± 35.30
IL-4	N/D	N/D	N/D	N/D	N/D
CSF-1 + IL-4	76.60 ± 3.90^*	218.80 ± 6.10	61.90 ± 2.00	223.00 ± 45.90	136.80 ± 1.10
IL-13	N/D	N/D	N/D	N/D	N/D
CSF-1 + IL-13	88.20 ± 1.20^*	320.90 ± 6.40^*	127.00 ± 3.40^*	216.50 ± 8.80^*	190.80 ± 2.90
IL-10	N/D	N/D	N/D	N/D	N/D
CSF-1 + IL-10	64.20 ± 1.30^*	295.10 ± 7.80^*	65.00 ± 5.40	175.70 ± 1.50^*	133.00 ± 0.70

^{^a}

Percent of positive cells and mean fluorescent intensity values are presented as mean ± SD of three to five independent experiments performed in duplicate on day 6.

^{^b}

Analysis was performed on the day of cell isolation.

Asterisks indicate statistically significant increases compared with CSF-1 alone determined by Student's t-test.

N/D, not done; analyses were not performed due to poor cell survival.